tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Monte Rosa, 3 are a BUY (60%), 2 are a HOLD (40%).
Analyst Monte Rosa, currently employed at UBS, carries an average stock price target met ratio of 100% that have a potential upside of 147.9% achieved within 611 days. Previously, Monte Rosa worked at CREDIT SUISSE, JPMORGAN, GUGGENHEIM.
Monte Rosa’s has documented 9 price targets and ratings displayed on 1 stocks.
Most recent stock forecast was given on GLUE, Monte Rosa Therapeutics at 29-Apr-2024.
Analyst best performing recommendations are on GLUE (MONTE ROSA THERAPEUTICS).
The best stock recommendation documented was for GLUE (MONTE ROSA THERAPEUTICS) at 7/19/2021. The price target of $30 was fulfilled within 16 days with a profit of $10.18 (51.36%) receiving and performance score of 32.1.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 03-Jan-2022
$35
$18.48 (111.86%)
$30
1 months 6 days ago
(30-Jun-2026)
0/4 (0%)
$10.8 (44.63%)
Buy Since 08-Jan-2026
$29
$12.48 (75.54%)
$30
4 months 18 days ago
(18-Mar-2026)
5/7 (71.43%)
$13.24 (84.01%)
658
Buy Since 19-Jul-2021
$37
$20.48 (123.97%)
$16
6 months 22 days ago
(14-Jan-2026)
3/5 (60%)
$12.94 (53.78%)
368
Buy Since 15-Aug-2022
$22
$5.48 (33.17%)
$20
7 months 19 days ago
(17-Dec-2025)
2/2 (100%)
$5.25 (31.34%)
631
Buy Since 15-Feb-2024
$26
$9.48 (57.38%)
7 months 20 days ago
(16-Dec-2025)
3/4 (75%)
$7.34 (39.34%)
506
What Year was the first public recommendation made by Monte Rosa?
